• 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Jagsi R Hawley ST Griffith KA


    20. Jagsi R, Hawley ST, Griffith KA, et al. Contralateral prophylactic mastectomy decisions in SC 560 population-based sample of patients with early-stage breast cancer. JAMA Surg. 2017;152:274e282.
    21. Storm-Dickerson T, Das L, Gabriel A, Gitlin M, Farias J, Macarios D. What drives patient choice: preferences for approaches to surgical treatments for breast cancer beyond traditional clinical benchmarks. Plast Reconstr Surg Glob Open. 2018;6:e1746.
    22. Nekhlyudov L, Bower M, Herrinton LJ, et al. Women’s decision-making roles regarding contralateral prophylactic mastectomy. J Natl Cancer Inst Monogr. 2005;2005:55e60.
    23. Frost MH, Slezak JM, Tran NV, et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol. 2005;23:7849e7856.
    24. Frost MH, Hoskin TL, Hartmann LC, Degnim AC, Johnson JL, Boughey JC. Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits. Ann Surg Oncol. 2011;18:3110e3116.
    25. Anderson C, Islam JY, Elizabeth Hodgson M, et al. Long-term satisfaction and body image after contralateral prophylactic mastectomy. Ann Surg Oncol. 2017;24:1499e1506.
    26. Lantz PM, Janz NK, Fagerlin A, et al. Satisfaction with surgery outcomes and the decision process in a population-based sample of women with breast cancer. Health Serv Res. 2005;40:745e768.
    27. Moyer A, Salovey P. Patient participation in treatment decision making and the psychological consequences of breast cancer surgery. Womens Health. 1998;4:103e116.
    28. Chewning B, Bylund CL, Shah B, Arora NK, Gueguen JA, Makoul G. Patient preferences for shared decisions: a systematic review. Patient Educ Couns. 2012;86:9e18.
    30. Smith SK, Dixon A, Trevena L, Nutbeam D, McCaffery KJ. Exploring patient involvement in healthcare decision making across different education and functional health literacy groups. Soc Sci Med. 2009;69:1805e1812. + MODEL
    Acta Pharmaceutica Sinica B xxxx;xxx(xxx):xxx
    Chinese Pharmaceutical Association
    Institute of Materia Medica, Chinese Academy of Medical Sciences
    Acta Pharmaceutica Sinica B
    Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer
    Dong Meia,b, Binlong Chenb, Bing Heb, Haibin Liuc, Zhiqiang Lind, Jialiang Linb, Xiaoyan Zhanga, Ning Suna, Libo Zhaoa, Xiaoling Wanga,*, Qiang Zhangb,*
    aClinical Research Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China
    bKey Laboratory of Molecular Pharmaceutics, New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China cDepartment of General Surgery, China-Japan Friendship Hospital, Beijing 100029, China dInstitute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China
    Autophagic cell death; Combination therapy; Targeted delivery; Rapamycin; Breast cancer;
    Transferrin receptor;
    Abstract Recently, considerable attention in the field of cancer therapy has been focused on the mammalian rapamycin target (mTOR), inhibition of which could result in autophagic cell death (ACD). Though novel combination chemotherapy of autophagy inducers with chemotherapeutic agents is extensively investigated, nanomedicine-based combination therapy for ACD remains in infancy. In attempt to actively trigger ACD for synergistic chemotherapy, here we incorporated autophagy inducer rapamycin (RAP) into 7pep-modified PEG-DSPE polymer micelles (7pep-M-RAP) to specifically target and efficiently priming ACD of MCF-7 human breast cancer cells with high expression of transferrin re-ceptor (TfR). Cytotoxic paclitaxel (PTX)-loaded micelle (7pep-M-PTX) was regarded as chemothera-peutic drug model. We discovered that with superior intracellular uptake in vitro and more tumor accumulation of micelles in vivo, 7pep-M-RAP exhibited excellent autophagy induction and synergistic antitumor efficacy with 7pep-M-PTX. Mechanism study further revealed that 7pep-M-RAP and 7pep-M-PTX used in combination provided enhanced efficacy through induction of both apoptosis- and